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Objectives
The current World Health Organization and Uganda Ministry of Health HIV treatment guidelines
recommend that asymptomatic patients who have a viral load (VL) ≥ 1000 HIV-1 RNA copies/mL
should receive adherence counselling and repeat VL testing before switching to second-line
therapy. We evaluated the effectiveness of this strategy in a large HIV treatment programme of
The AIDS Support Organisation Jinja in Jinja, Uganda.
Methods
We measured the HIV VL at enrolment, and for participants with VL ≥ 1000 copies/mL we informed
them of their result, offered enhanced adherence counselling and repeated the VL measurement after
3 months. All blood samples with VL ≥ 1000 copies/mL were sequenced in the polymerase (pol)
region, a 1257-bp fragment spanning the protease and reverse transcriptase genes.
Results
One thousand and ninety-one participants were enrolled in the study; 74.7% were female and the
median age was 44 years [interquartile range (IQR) 39–50 years]. The median time on antiretroviral
therapy (ART) at enrolment was 6.75 years (IQR 5.3–7.6 years) and the median CD4 cell count was
494 cells/lL (IQR 351–691 cells/lL). A total of 113 participants (10.4%) had VLs ≥ 1000 copies/mL
and were informed of the VL result and its implications and given adherence counselling. Of these
113 participants, 102 completed 3 months of follow-up and 93 (91%) still had VLs ≥ 1000 copies/
mL. We successfully genotyped HIV for 105 patients (93%) and found that 103 (98%) had at least
one mutation: eight (7.6%) had only one mutation, 94 (89.5%) had two mutations and one sample
(1%) had three mutations.
Conclusions
In this study, enhanced adherence counselling was not effective in reversing virologically defined
treatment failure for patients on long-term ART who had not previously had a VL test.
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Introduction
There has been a dramatic expansion of access to antiretro-
viral therapy (ART) in sub-Saharan Africa over the past
two decades, with 21.7 million people accessing ART by
the end of 2017 [1]. Until recently, most of this expanded
access occurred through programmes that did not offer
routine viral load (VL) monitoring, in keeping with earlier
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guidance from the World Health Organization (WHO)
which did not explicitly recommend VL testing for patients
on ART in resource-limited settings [2,3]. This practice had
been supported by the results of randomized clinical trials
which found no added clinical benefit of the addition of
routine VL monitoring for patients on ART when compared
to CD4 cell count monitoring alone [4–7].
However, more recently, WHO guidelines for HIV care
and treatment in resource-limited settings were revised to
recommend routine VL testing as the preferred tool for
diagnosing ART treatment failure [8] as it provides a
more accurate indication of ART treatment failure and
hence avoids unnecessary switches to second-line therapy
[9,10]. It is also expected that treatment failure could be
detected earlier and therefore should reduce the number
and severity of drug-resistance mutations accumulated in
patients who are failing therapy [10]. VL results can also
help health care providers to differentiate between non-
adherence and ART treatment failure caused by resistance
[9]. Additionally, there have been recent findings from a
systematic review indicating that clinical and immuno-
logical approaches for diagnosing treatment failure have
low sensitivity and positive predictive value in identify-
ing persons with virological failure [11].
Consequently, many national ART programmes in sub-
Saharan African countries are now adopting the revised
WHO recommendations and many programmes that did
not provide VL testing may have begun using this as an
additional monitoring tool. In sub-Saharan Africa, seven
countries, South Africa, Tanzania, Co^te d’Ivoire, Kenya,
Malawi, Namibia and Uganda, are reported to be at vari-
ous stages of scaling up routine VL monitoring [12].
In Uganda, the 2013 national ART treatment guidelines
recommend that VL testing should be conducted 6 months
after initiation of therapy and annually thereafter [13].
Both the WHO and the Ugandan ART guidelines recom-
mend that asymptomatic patients who have been identified
with VL ≥ 1000 copies/mL should be offered enhanced
adherence counselling for 3–6 months and repeat VL test-
ing before switching to second-line therapy [3,14]. Viro-
logical treatment failure is confirmed after two consecutive
plasma VL test results ≥ 1000 copies/mL obtained 3–
6 months apart, with enhanced adherence counselling and
support following the first VL test [13,14].
However, little is known about the effectiveness of
counselling and adherence support interventions in
reversing virological failure in long-term HIV-positive
patients, particularly in those who have been receiving
ART for long periods of time without prior VL testing.
We designed a study to evaluate the effectiveness of
enhanced adherence counselling and support for patients
identified with VL ≥ 1000 copies/mL at their first VL test,
among individuals who had been receiving ART for ≥
4 years in an HIV treatment programme in which VL
testing was not routinely available. Furthermore, we eval-
uated factors associated with successful reversal of viro-
logical failure, including ART drug resistance patterns, in
these patients.
Methods
In June 2012, we initiated a prospective cohort study
titled the Long-term Outcome on Antiretroviral Therapy
Study in Uganda (LTOAU). This study recruited HIV-posi-
tive patients who were receiving care at The AIDS Sup-
port Organisation (TASO) Jinja service centre, and had
been receiving ART for a minimum of 4 years.
The AIDS Support Organisation Jinja is one of the 11
HIV clinics of TASO, the largest nongovernmental organi-
zation in Uganda providing HIV care in the country. The
TASO Jinja clinic is located in Jinja District, in the east-
central region of Uganda, and serves persons in the dis-
trict and other neighbouring districts within a radius of
75 km. Jinja District has a population of 468 256 and,
like its neighbouring areas, is largely rural; the average
annual income per household is estimated to be US$100,
and the majority of inhabitants are subsistence farmers,
with very few working in the formal sector and earning
wages [15,16].
The ART programme in TASO Jinja began in 2004, and
has over 5000 HIV-positive persons receiving therapy. All
patients are commenced on ART in accordance with
Ugandan national ART guidelines which recommend
first-line regimens with two nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs) plus one nonnucleoside
reverse transcriptase inhibitor (NNRTI). Second-line regi-
mens preferentially include two NRTIs not used in the
first-line regimen and a protease inhibitor (PI), most com-
monly lopinavir-ritonavir. During the period of our study,
VL monitoring was not provided routinely; however,
immunological (CD4 cell count testing) and clinical mon-
itoring was carried out every 6 months in accordance
with the Ugandan national ART guidelines [13,14].
We recruited HIV-positive patients aged ≥ 18 years
who had presented for clinical care at the TASO Jinja
clinic or outreach sites between 1 July 2012 and 31
December 2013 and had been receiving first-line ART for
≥ 4 years. We excluded patients who had ever received a
lopinavir-ritonavir-containing regimen.
From June 2012 to July 2013, we provided an infor-
mation sheet about the proposed study to all TASO Jinja
patients who had been receiving ART for a minimum of
4 years. After providing informed consent, participants
completed an interviewer-administered questionnaire and
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had blood drawn for VL and CD4 cell count testing. We
collected clinical, demographic and behavioural data at
the first study visit and all participants continued to
receive routine care from the TASO clinical teams every
3 months. After August 2013, we further restricted enrol-
ment to patients whose last CD4 cell count was
≤ 450 cells/lL and continued recruitment until January
2015. This restriction was decided upon following an
interim analysis that demonstrated that the prevalence of
virological failure among patients with a CD4 cell count
of > 450 cells/lL was < 2%. We therefore took this step
to increase the diagnostic yield of identifying patients
with VL ≥ 1000 copies/mL.
We measured the HIV VL at enrolment and, for partici-
pants with a VL ≥ 1000 copies/mL, we informed them of
the result and its interpretation and offered enhanced
adherence counselling. This consisted of additional monthly
face-to-face sessions with the counsellor for three consecu-
tive months. During this session, the counsellor discussed
the implications of unsuppressed VL, established the
patient’s adherence level, and, together with the patient,
reviewed the previous adherence strategies to develop a
revised adherence plan. Where possible, the ‘treatment bud-
dies’ were re-contacted during this period. These partici-
pants then had a repeat VL measurement 3 months after the
first test to determine if they still had virological failure.
In our study, if participants met the criteria for clinical
failure, they were offered switches to second-line therapy
after the first visit, but otherwise decisions about chang-
ing ART regimens (including decisions for patients with
immunological failure) were deferred until after the
3 months of enhanced adherence counselling support.
Additional social and behavioural data were collected at
the 3-month study visit for those with virological failure.
Adherence was measured based on self-reported
responses to two questions: (1) ‘In general, how often do
you miss taking your ARV pills?’ (reponses: never; once
a month or less; more than once a month but less than
once a week; and once a week or more) and (2) ‘In this
past month how many of your ARV pills have you
missed taking?’ (responses: 0, 1, 2, 3, 4, 5 and > 5).
HIV VL was measured with the COBAS Ampliprep/Taq-
Man HIV-1 test V2.0 (Roche, Mannheim, Germany) at the
Uganda Virus Research Institute (UVRI)/Medical Research
Council (UK) laboratory in Entebbe. All blood samples
with a VL ≥ 1000 copies/mL were sequenced in the poly-
merase (pol) region, a 1257-bp fragment spanning the
protease and reverse transcriptase genes, as previously
described [17]. The study received approval from the
Research Ethics Committee of UVRI, the Uganda National
Council for Science and Technology in Uganda and the
University of British Columbia in Vancouver, Canada.
Virological failure was defined as having a VL ≥ 1000
copies/mL at enrolment and after 3 months of enhanced
adherence counselling support.
We obtained descriptive statistics of characteristics of
the entire study population including those with VL
≤ 1000 copies/mL at enrolment and included all the
explanatory and outcome variables of interest. As multiple
thymidine analogue mutations (TAMs) have the greatest
propensity to reduce the effectiveness of second-line regi-
mens in use in low-income countries, we conducted bivari-
ate analyses comparing participants who had zero or one
TAM with those with at least two TAMs using Wilcoxon
rank sum tests for continuous variables and v2 or Fisher’s
exact test for categorical variables. We then conducted a
subsequent bivariate analysis comparing participants on
the basis of correction of virological failure after an addi-
tional 3 months of follow-up. All analyses were conducted
using SAS Version 9.3 (SAS Corporation, Cary, NC).
Results
A total of 1091 participants were enrolled in the study, of
whom 815 (74.7%) were female, and the median age was
44 years [interquartile range (IQR) 39–50 years]. The
median time on ART at enrolment was 6.75 years (IQR
5.3–7.6 years) and the median CD4 cell count at enrol-
ment was 494 cells/lL (IQR 351–691 cells/lL). The most
common regimen taken by participants at the time of
enrolment in this study was nevirapine, lamivudine and
zidovudine (72.7% of participants) followed by efavirenz,
lamivudine and zidovudine (18.3%) and nevirapine, lami-
vudine and tenofovir (7.4%). However, 555 participants
(50.9%) reported receiving other drug regimens since
beginning ART. Of these, the most commonly received
ART regimen was nevirapine, lamivudine and stavudine
(407 participants or 73.3% of those with previous regi-
mens). A total of 667 (61.3%) participants reported never
missing a dose of their ART and 865 (79.6%) reported not
missing any doses in the previous month (Table 1).
While we were unable to quantify the number of indi-
viduals who were ineligible for this study because of pre-
vious switches to lopinavir-containing ART regimens, by
the end of 2014 (during our recruitment and enrolment
period), there were approximately 265 clients of TASO
Jinja who were receiving second-line therapy, out of
approximately 5855 patients on ART [18].
Among the 1091 patients screened at enrolment, a total
of 113 (10.4%) had VLs ≥ 1000 copies/mL. Of these 1091
patients, 870 were enrolled irrespective of their CD4 cell
counts, of whom 61 had virological failure (prevalence of
7.0%). The analysis comparing those participants in our
study with VLs ≥ 1000 copies/mL to those with VLs
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< 1000 copies/mL is reported elsewhere [19]. When we
restricted enrolment to those with CD4 cell counts
≤ 450 cells/lL, we found an additional 52 participants
with virological failure out of 221 enrollees (prevalence
of 23.5%).
For the 113 (61 plus 52) participants with HIV VL
≥ 1000 copies/mL at enrolment, we were able to success-
fully genotype 105 (93%) of the samples. Of these, 103
(98%) had at least one mutation, eight (7.6%) had only
one mutation, 94 (89.5%) had two mutations and one
sample (1%) had three mutations. A total of 100 samples
(95.2%) had NRTI mutations and 98 (93.3%) had NNRTI
mutations. Only one sample (1%) had a mutation
conferring resistance to PIs. Among the 105 samples,
M184V was the most frequent mutation found, occurring
in 95 samples (90.5%), followed by Y181C which
occurred in 42 samples (40.0%). A total of 12 samples
(11.4%) had K65R mutations; 69 patients (65.7%) had at
least one TAM and 53 (50.5%) had at least two TAMs
(Table 2).
Having two or more TAMs was more common among
participants with; < 1 year of primary school education
(24.5% of those with at least two TAMs versus 7.7% of
those with zero or one TAM), previous regimen that
included nevirapine, lamivudine and stavudine (96.0% vs.
62.5%; p=0.002) and an enrollment VL ≥100,000 copies/
mL (43.4% vs. 26.9%; p=0.001). Participants with at least
two TAMs also had lower CD4 cell counts at the first
study visit (median of 179 versus 263 cells/lL in those
with zero or one TAM; P = 0.004) and had been receiving
ART for a longer period of time (median of 6.8 versus
6.2 years, respectively; P = 0.026) (Table 3).
All the 113 patients were informed of the VL result
by the study nurse or physician and given enhanced
adherence counselling and support by a counsellor. Of
these, 102 completed follow-up at the 3-month study
visit and 93 (91%) still had VL ≥ 1000 copies/mL after
Table 1 Characteristics of the 1091 participants at their enrolment
visit
Characteristic Category n %
Gender Female 815 74.7
Male 276 25.3
Income source Agriculture 335 30.7
Wage/salaried employment 143 13.1
Crafts trade 66 6.1
Petty trade 276 25.3
None 91 8.3
Other 180 16.5
Education level Low 224 20.5
Medium 493 45.2
High 374 34.3
Marital status Legally married 188 17.2
Cohabiting 269 24.7
Single/separated/divorced 220 20.2
Widowed 414 38.0
Years in TASO < 2 years 10 0.9
2 to < 5 years 41 3.8
≥ 4 years 1039 95.3
ARV regimen at enrolment Efavirenz/3TC/TDF 21 1.9
Efavirenz/3TC/ZDV 200 18.3
Nevirapine/3TC/TDF 81 7.4
Nevirapine/3TC/ZDV 787 72.1
Other ARV regimen 2 0.2
Been on previous ARV No 536 49.1
Yes 555 50.9
Previous ARV regimen Efavirenz/3TC/TDF 2 0.4
Efavirenz/3TC/ZDV 27 4.9
Efavirenz/3TC/d4T 52 9.4
Nevirapine/3TC/TDF 8 1.4
Nevirapine/3TC/ZDV 59 10.6
Nevirapine/3TC/d4T 407 73.3
ARV adherence: Never 667 61.3
frequency reported of missing
taking pills
Once a month or less 269 24.7
More than once a week but
less than once a month
85 7.8
Once a week or more 67 6.2
Number of ARV pills reported
missing in past month
One or more 222 20.4
None 865 79.6
Viral load ≥ 1000 copies/mL No 978 89.6
Yes 113 10.4
ARV, antiretroviral; TASO, The AIDS Support Organisation; 3TC, lamivu-
dine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine; d4T, stavu-
dine.
Table 2 Frequency of antiretroviral therapy (ART) resistance muta-
tions among participants with viral load ≥ 1000 copies/mL
(n = 105)
n %
ART class mutations
NNRTI resistance mutations 98 93.3
PI resistance mutations 1 1.0
NRTI resistance mutations 100 95.2
TAMs 69 65.7
Other NRTI resistance mutations 31 29.5
Individual mutations
M184V 95 90.5
Y181C 42 40.0
K103N 36 34.3
M41 l* 34 32.4
T215Y* 30 28.6
K70R* 25 23.8
G190A 23 21.9
L210W* 21 20.0
T215F* 19 18.1
D67N* 18 17.1
K219Q* 15 14.3
K219E* 13 12.4
K65R 12 11.4
K101E 7 6.7
P225H 6 5.7
Others 33 31.4
NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside
reverse transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine
analogue mutation.
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3 months. Comparing the nine (8.8%) participants who
achieved a VL < 1000 copies/mL on the second test
with those who did not, we found that a lower propor-
tion of them had two or more drug mutations (50%
versus 93%, respectively; P = 0.010), NNRTI drug resis-
tance mutations (67% versus 95.5%, respectively;
P = 0.046) and NRTI resistance mutations (67% versus
98%, respectively; P = 0.019). We also found that none
of those who achieved virological suppression had two
or more TAMs compared to 51% of participants who
remained unsuppressed (P = 0.027). Furthermore, fewer
participants who achieved virological suppression had
M184 mutations compared to those who remained
unsuppressed (50% versus 95%, respectively; P = 0.005).
Of the nine participants, four (44%), who had a VL
between 1000 and 5000 copies/mL, were able to reverse
their virological failure. However, for participants with
VL > 5000 copies/mL, enhanced adherence support did
not achieve a reduction in VL of > 10% (Table 4).
Of the 11 participants who did not have a repeat VL
test conducted at 3 months, three died before their 3-
month visit, another four were switched to second-line
therapy before their 3-month visit, one was lost to fol-
low-up and another four were more than 1 month late
for their repeat VL test. In total, 97 (86%) of those with
virological failure were switched to second-line therapy
either before or after their 3-month visit.
Discussion
In this study, enhanced adherence counselling was largely
ineffective in reversing virologically defined treatment
failure for patients on long-term ART (patients on ART
for ≥ 4 years) who had not previously had a VL test. Only
Table 3 Bivariate analysis comparing participants with viral load (VL) ≥ 1000 copies/mL and at least two thymidine analogue mutations
(TAMs) with participants with VL ≥ 1000 copies/mL and fewer than two TAMs
Characteristic
0 or 1 TAM (52) ≥ 2 TAMs (53)
P-valuen or median % or IQR n or median % or IQR
Gender
Female 36 69.2 39 73.6 0.670
Male 16 30.8 14 26.4
Age 42 37–46 39 34–44 0.046
Income source
Agriculture 12 23.1 15 28.3 0.057
Wage or salaried employment 11 21.2 10 18.9
Crafts trade 4 7.7
Petty trade 12 23.1 17 32.1
None 7 13.5 1 1.9
Other 6 11.5 10 18.9
Education
No formal education or < 1 year of primary 4 7.7 13 24.5 0.040
Some primary education 29 55.8 20 37.7
Some secondary school education 19 36.5 20 37.7
Duration of antiretroviral therapy (years) 6.2 4.7–7.2 6.8 6.0–7.7 0.026
ARV regimen at first study visit
Efavirenz/3TC/TDF 2 3.9 0.064
Efavirenz/3TC/ZDV 5 9.6 6 11.3
Nevirapine/3TC/TDF 10 19.2 3 5.7
Nevirapine/3TC/ZDV 35 67.3 44 83.0
Previous ARV regimen
Efavirenz/3TC/TDF 0 0 0 0 0.002
Efavirenz/3TC/ZDV 1 4.2 0 0
Efavirenz/3TC/d4T 1 4.2 0 0
Nevirapine/3TC/TDF 0 0 1 4.0
Nevirapine/3TC/ZDV 7 29.2 0 0
Nevirapine/3TC/d4T 15 62.5 24 96.0
CD4 count at enrolment (cells/lL) 263 147–407 179 101–253 0.004
Viral load at enrolment
1000–5000 copies/mL 7 13.5 0 0
5000–10 000 copies/mL 4 7.7 4 7.6
10 000–50 000 copies/mL 24 46.2 14 26.4
50 000–100 000 copies/mL 3 5.8 12 22.6
> 100 000 copies/mL 14 26.9 23 43.4
ARV, antiretroviral; IQR, interquartile range; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine; d4T, stavudine.
© 2019 The Authors.
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Table 4 Virological failure after 3 months of adherence counselling intervention
Characteristic Category
Virological failure after 3 months
P-value
No Yes
(n = 9) (n = 93)
Age (years) [median (IQR)] 45 (36–52) 41 (36–44) 0.193
Gender [n (%)] Female 7 (77.8) 70 (75.3) 1.000
Male 2 (22.2) 23 (24.7)
Income source [n (%)] Agriculture 1 (11.1) 23 (24.7) 0.063
Wage/salaried employment 0 (0) 21 (22.6)
Crafts trade 1 (11.1) 3 (3.2)
Petty trade 3 (33.3) 30 (32.3)
None 2 (22.2) 4 (4.3)
Other 2 (22.2) 12 (12.9)
Education [n (%)] Low 2 (22.2) 13 (14.0) 0.212
Medium 6 (66.7) 44 (47.3)
High 1 (11.1) 36 (38.7)
≥ 4 years in The AIDS Support Organisation [n (%)] No 1 (11.1) 6 (6.5) 0.487
Yes 8 (88.9) 87 (93.6)
CD4 at enrolment [median (IQR)] 364 (308–423) 220 (129–335) 0.053
Time on ARV at enrolment (months) [median (IQR)] 62 (57–90) 79 (61–92) 0.942
ARV regimen at enrolment [n (%)] Efavirenz/3TC/TDF 1 (11.1) 2 (2.2) 0.046
Efavirenz/3TC/ZDV 3 (33.3) 8 (8.6)
Nevirapine/3TC/TDF 1 (11.1) 13 (14.0)
Nevirapine/3TC/ZDV 4 (44.4) 70 (75.3)
Been on previous ARV No 4 (44.4) 51 (54.8) 0.729
Yes 5 (55.6) 42 (45.2)
Previous ARV regimen (n = 47) Efavirenz/3TC/ZDV 1 (20) 2 (4.8) 0.123
Efavirenz/3TC/d4T 0 (0) 1 (2.4)
Nevirapine/3TC/ZDV 2 (40) 6 (14.3)
Nevirapine/3TC/d4T 2 (40) 33 (78.6)
ARV adherence (n = 100) Never 6 (66.7) 49 (53.9) 0.772
Frequency of missing taking pills [n (%)] Once a week 5 (5.5)
More than once a week but less than
once a month
1 (11.1) 6 (6.6)
More than once a month 2 (22.2) 31 (34.1)
Good ARV adherence (n = 100) No 3 (33.3) 20 (22.0) 0.426
Did not miss any pill in the past month Yes 6 (66.7) 71 (78)
Frequency of medicine companions observations in 7 days before
enrolment [median (IQR)]
11 (7–14) 7 (4–14) 0.363
Switching to second-line therapy (n = 93) No 3 (3.2)
Yes 90 (96.8)
Baseline viral load [n (%)] 1000–5000 copies/mL 4 (44.4) 5 (5.8) < 0.001
5000–10 000 copies/mL 1 (11.1) 8 (8.6)
10 000–50 000 copies/mL 39 (41.9)
50 000–100 000 copies/mL 13 (14.0)
> 100 000 copies/mL 4 (44.4) 28 (30.1)
> 1000 [n (%)] Yes 9 (100) 93 (100) n/a
> 5000 [n (%)] Yes 5 (55.6) 88 (94.6) 0.003
> 10 000 [n (%)] Yes 4 (44.4) 80 (86.0) 0.008
> 50 000 [n (%)] Yes 4 (44.4) 41 (44.1) 1.0000
Any drug resistance mutations (n = 93) Yes 5 (83.3) 88 (100) 0.064
Two or more drug class mutations [n (%)] Yes 3 (50) 82 (93.2) 0.010
Any NNRTI drug resistance [n (%)] Yes 4 (66.7) 84 (95.5) 0.046
Any PI mutation [n (%)] Yes 1 (1.1) 1.000
Any NRTI mutation [n (%)] Yes 4 (66.7) 86 (97.7) 0.019
Any TAM [n (%)] Yes 2 (33.3) 58 (65.9) 0.185
≥ 2 TAMs [n (%)] Yes 0 (0) 45 (51.1) 0.027
Any other NRTI mutation [n (%)] Yes 2 (33.3) 28 (31.8) 1.000
K65R mutation [n (%)] Yes 1 (16.7) 11 (12.5) 0.570
M184V mutation [n (%)] Yes 3 (50.0) 84 (95.5) 0.0047
ARV, antiretroviral; IQR, interquartile range; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine; d4T, stavudine; NRTI, nucleotide
reverse transcriptase inhibitor; NNRTI, nucleotide reverse transcriptase inhibitor; TAM, thymidine analogue mutation.
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9% of the participants who were found to have a VL of
≥ 1000 copies/mL at enrolment were able to achieve a VL
of < 1000 copies/mL after 3 months of enhanced adher-
ence counselling and support. These results suggest that
current national and international guidelines recommend-
ing that enhanced adherence counselling and repeat VL
testing be offered to such patients on long-term ART
should be reconsidered. Switching patients who have
been receiving ART for long periods of time on the basis
of a single VL result would probably result in more rapid
reversal of virological failure and a much shorter dura-
tion of unsuppressed viraemia and reduced potential
transmission of drug-resistant virus. Our study also found
a high frequency of NRTI and NNRTI resistance mutations
among the participants with virological failure, with
M184V being the most common followed by Y181C.
This is similar to what has been reported in other studies
[20–22].
We also noted a very high prevalence of TAMs, with
65% of those with virological failure having at least one
TAM and 50% having two or more TAMs; similar preva-
lences have been reported in other studies for patients
receiving regimens containing stavudine, zidovudine,
lamivudine, efavirenz and nevirapine [22–24]. However, a
lower prevalence of TAMs of between 5 and 25% has
been reported in a retrospective multicentre cohort study
in sub-Saharan Africa among patients using tenofovir
[25]. As many second-line regimens in sub-Saharan
Africa will by necessity include didanosine and abacavir,
which can have reduced effectiveness in the presence of
increasing numbers of TAMs [26], these are probably the
most concerning mutation patterns we found. Previous
exposure to stavudine was associated with having two or
more TAMs in our study. However, given that stavudine
is no longer being prescribed in Uganda [13,27] and in
most resource-limited settings in accordance with the
WHO ART guidelines [8], this issue will probably be less
of a problem in the future, which is somewhat reassuring.
Fortunately, we also found a fairly low prevalence of the
K65R mutation (in 11% of individuals with virological
failure), which is another NRTI resistance mutation that
can confer pan-NRTI resistance, although one study
reported that K65R mutations are likely to increase with
increased use of tenofovir as a first-line option [17]. VL
measurement with enhanced adherence counselling has
been demonstrated to be effective for individuals who are
in the first few years of ART in South Africa [20,28,29].
However, our findings regarding adherence counselling
for patients who had been receiving ART for longer peri-
ods of ≥ 4 years are similar to the findings from a study
in Swaziland which reported that, among patients receiv-
ing ART for a median of 2.9 years (IQR 1.6–4.6 years),
those who were found to have raised VLs (VL
≥ 1000 copies/mL) and received enhanced adherence
counselling by counsellors were no more likely to achieve
VL suppression at subsequent VL test than those who did
not receive counselling [30]. Another study in Khayelit-
sha in South Africa reported higher rates of virological
re-suppression among patients failing on second-line
ART following enhanced adherence support [31]. How-
ever, patients in this study had been on second-line ART
for a short period of time, a median of 1.7 years (IQR
0.9–2.5 years), and were using lopinavir-based second-
line therapy rather than NNRTI-based first-line therapy.
A systematic review of 29 studies on rates of emergence
of HIV drug resistance in resource-limited settings
revealed that the rates increased steadily with time on
ART. Enhanced adherence counselling may not be effec-
tive in situations where virological failure is likely to
have occurred months or years before diagnosis, and
patients will probably already have developed resistance
mutations that even good adherence may not overcome.
It is worth noting that, in our study, in cases where viro-
logical failure was reversed, the initial median VL was
< 10 000 copies/mL and CD4 cell counts tended to be
higher.
The occurrence of three deaths in the 3-month period
between the first and second VL results implies that mor-
tality may be quite high among this population. While it
is not clear whether switching medications earlier would
have prevented these deaths, it is also not known if more
deaths would have occurred had the study used the rec-
ommended upper limit of 6 months for the period
between the two results, according to Uganda MoH ART
guidelines [13,14].
This study had a number of limitations. Firstly, adher-
ence measures were self-reported and could reflect under-
estimates of true nonadherence, as has been reported in
studies elsewhere [32]. However, adherence to therapy
among participants in this study must have been suffi-
cient to allow participants to survive ≥ 4 years on ART.
Secondly, while we had a relatively large sample size of
patients on long-term ART (> 1000), the proportion of
those with virological failure was quite low at 7.0%, leav-
ing a fairly small sample in which to study the effect of
enhanced adherence counselling. This ‘limitation’, how-
ever, again demonstrates that TASO has done an excel-
lent job in promoting ART adherence among programme
participants. Programmes with greater proportions of
nonadherent participants and those with treatment failure
may find more value in promoting adherence. However,
given the persistent impact of the NNRTI and NRTI resis-
tance mutations that develop among individuals failing
first-line therapy, this may not, in fact, be true.
© 2019 The Authors.
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In conclusion, our study found that enhanced
adherence counselling was not effective in reversing
virologically defined treatment failure for patients on
long-term ART who had not previously had a VL test.
Thus, recommendations that all patients with virological
failure should undergo a period of enhanced counselling
and re-measuring of VL before changing their therapy
should be revisited. Our findings also highlight the need
for timely HIV resistance testing for patients receiving
ART in sub-Saharan Africa with unsuppressed VL at first
measurement. It remains to be seen whether the resis-
tance patterns we observed in this cohort will impact the
longer term clinical and virological outcomes of these
patients.
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